THERORNA
LIVE

Serial Number

90796130

Owner

THERORNA Inc.

Attorney

Paulo A. de Almeida

Filing Date

Jun 25, 2021

Add to watchlist:

No watchlists yet
View on USPTO

THERORNA Trademark

Serial Number: 90796130 • Registration: 7159975

THERORNA is a trademark filed by THERORNA Inc. on June 25, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

THERORNA Inc. (7 trademarks)

3302C, BUILDING 2, 1 TIANDI LINFENG
DISTRICT, BEIJING 100082 , CN

Entity Type: 03

Trademark Details

Filing Date

June 25, 2021

Registration Date

September 12, 2023

Published for Opposition

June 27, 2023

Goods & Services

Pharmaceutical preparations for human biomedicine, namely, pharmaceutical preparations used for protein replacement therapy, cardiovascular therapy, liver disease therapy, cancer therapy, respiratory disease therapy, infectious disease therapy, neurological disease therapy, and for use as a new coronavirus vaccine; vaccines; drugs for medical purposes, namely, medicinal preparations used for protein replacement therapy, cardiovascular therapy, liver disease therapy, cancer therapy, respiratory disease therapy, infectious disease therapy, neurological disease therapy, and for use as a new coronavirus vaccine; opotherapy preparations; serotherapeutic medicines, namely, medical immune serums used for protein replacement therapy, cardiovascular therapy, liver disease therapy, cancer therapy, respiratory disease therapy, infectious disease therapy, neurological disease therapy, and for use as a new coronavirus vaccine; biological preparations for medical purposes, namely, biological preparations used for protein replacement therapy, cardiovascular therapy, liver disease therapy, cancer therapy, respiratory disease therapy, infectious disease therapy, neurological disease therapy, and for use as a new coronavirus vaccine; medicines for human purposes, namely, medicines used for protein replacement therapy, cardiovascular therapy, liver disease therapy, cancer therapy, respiratory disease therapy, infectious disease therapy, neurological disease therapy, and new coronavirus vaccine; chemical preparations for medical purposes, namely, medicinal preparations used for protein replacement therapy, cardiovascular therapy, liver disease therapy, cancer therapy, respiratory disease therapy, infectious disease therapy, neurological disease therapy, and new coronavirus vaccine; adjuvants for medical purposes; Blood for medical purposes; nutraceutical preparations for therapeutic or medical purposes; immunostimulants; Medical cell function activating drugs, namely, medicinal preparations used for protein replacement therapy, cardiovascular therapy, liver disease therapy, cancer therapy, respiratory disease therapy, infectious disease therapy, neurological disease therapy, and for use as a new coronavirus vaccine; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; tumor suppressing agents; Anti-sarcoma preparations; cytostatics for medical purposes; Pharmaceutical products for the prevention and treatment of cancer; all the foregoing using circular ribonucleic acid (RNA)

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 12, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 12, 2023 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 27, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jun 27, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 7, 2023 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
May 19, 2023 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
May 12, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
May 12, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 12, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
May 12, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 12, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 1, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 1, 2022 CRFA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 1, 2022 TEME
ASSIGNED TO LIE
Nov 1, 2022 ALIE
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 19, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 19, 2022 TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 19, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 18, 2022 GNRN
NON-FINAL ACTION E-MAILED
Mar 18, 2022 GNRT
NON-FINAL ACTION WRITTEN
Mar 18, 2022 CNRT
ASSIGNED TO EXAMINER
Mar 16, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 9, 2021 NWOS
NEW APPLICATION ENTERED
Jun 29, 2021 NWAP